Latest Press Releases

Europes Main Computational Biology Conference Comes to Turku, Finland

Discoveries made when biology meets computational sciences are revolutionising the landscape of life sciences and healthcare. Computational biology and bioinformatics are driving this transformation helping researchers analyse vast amounts of ...

Phase 2 IMBRUVICA® (ibrutinib) Plus VENCLEXTA® (venetoclax) Early Data Show High Rates of Responses in Patients with Previously-Untreated Chronic Lymphocytic Leukemia (CLL)

- Approximately nine out of 10 of the first CLL patients treated achieved responses with no detectable minimal residual disease (MRD) based on a specific test to detect cancer cells in the bone marrow NORTH CHICAGO, Ill. , June 3, 2018 ...

Erdafitinib Phase 2 Study Results Show Promise in the Treatment of Metastatic Urothelial Cancer

Treatment with investigational compound erdafitinib demonstrated durable responses in patients with metastatic urothelial cancer with genetic alterations CHICAGO , June 3, 2018 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson ...

Merck KGaA, Darmstadt, Germany Presents Update on Tepotinib in Advanced Lung Cancer at ASCO 2018

DARMSTADT, Germany , June 3, 2018 /PRNewswire/ -- Not intended for UK-based media ASCO Abstract # Tepotinib (c-Met kinase inhibitor): 9082, 9016; M7824 (TGF-ß trap/anti-PD-L1): 3007, 9017, 2566; M2698 (dual p70S6k/Akt inhibitor): ...

Takeda Highlights Favorable Safety Profile of Entyvio® (vedolizumab) Through Comparative Real-World Data Versus TNFa-Antagonist Therapy in Ulcerative Colitis and Crohn's Disease

OSAKA, Japan , June 3, 2018 /PRNewswire/ -- Takeda demonstrates leadership in GI by featuring new U.S. VICTORY Consortium data among its 24 sponsored Entyvio abstracts presented at the Digestive Disease Week (DDW) 2018 meeting Takeda ...

Fiber Choice® Chewable Prebiotic Fiber Supplement Achieves #1-Recommended Status From Gastroenterologists Nationwide

- In a national survey, the Fiber Choice® line of chewable prebiotic fiber tablets and gummies, achieved the #1 share of gastroenterologist (GE) recommendations, more than four times greater than that for the nearest branded competitor BOCA ...

Forty Seven, Inc. Announces Proof-of-Concept Data from Two Clinical Trials of 5F9 In Patients with Advanced Solid Tumors and Non-Hodgkin's Lymphoma

-- 5F9 Safe and Well-Tolerated Using Proprietary Priming and Maintenance Dosing Strategy -- MENLO PARK, Calif. , June 3, 2018 /PRNewswire/ -- Forty Seven, Inc., a clinical-stage, immuno-oncology company focused on developing therapies to ...

SRK Knowledge Foundation Launched ‘India’s First Population Health Study’ in Wisdom - A Lecture of Series-2

SURAT, India , June 2, 2018 /PRNewswire/ -- SRK Knowledge Foundation conducted Wisdom - A lecture of Series-2 on 'Future of India ' in Science Centre, Surat on 29 th May 2018 . The Noble Laureate Shri Kailash Satyarthi, Children's Right ...

Press Releases

Premium Press Releases »

Europes Main Computational Biology Conference Comes to Turku, Finland

Press Releases »

Phase 2 IMBRUVICA® (ibrutinib) Plus VENCLEXTA® (venetoclax) Early Data Show High Rates of Responses in Patients with Previously-Untreated Chronic Lymphocytic Leukemia (CLL)

Erdafitinib Phase 2 Study Results Show Promise in the Treatment of Metastatic Urothelial Cancer

Merck KGaA, Darmstadt, Germany Presents Update on Tepotinib in Advanced Lung Cancer at ASCO 2018

Takeda Highlights Favorable Safety Profile of Entyvio® (vedolizumab) Through Comparative Real-World Data Versus TNFa-Antagonist Therapy in Ulcerative Colitis and Crohn's Disease

Fiber Choice® Chewable Prebiotic Fiber Supplement Achieves #1-Recommended Status From Gastroenterologists Nationwide

Forty Seven, Inc. Announces Proof-of-Concept Data from Two Clinical Trials of 5F9 In Patients with Advanced Solid Tumors and Non-Hodgkin's Lymphoma

SRK Knowledge Foundation Launched ‘India’s First Population Health Study’ in Wisdom - A Lecture of Series-2

Medindia Newsletters